Penmenvy Side Effects

Generic name: meningococcal group acwy conjugate-group b vaccine (cvx 328)

Note: This document provides detailed information about Penmenvy Side Effects associated with meningococcal group acwy conjugate-group b vaccine (cvx 328). Some dosage forms listed on this page may not apply specifically to the brand name Penmenvy.

Applies to meningococcal group acwy conjugate-group b vaccine (cvx 328): intramuscular powder for injection.

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Keep track of all side effects you have, be sure to tell the vaccination provider if the previous shot caused any side effects.

Becoming infected with meningococcal disease and developing meningitis is much more dangerous to your health than receiving this vaccine. Any vaccine may cause side effects but the risk of serious side effects is low.

You should not receive a second shot if you had a life-threatening allergic reaction after the first shot.

Common side effects may include:

• pain, redness, swelling, or irritation where the medicine was injected;

• feeling tired;

• headache;

• muscle or joint pain; or

• nausea.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

See also:

For healthcare professionals

Applies to meningococcal group acwy conjugate-group b vaccine (cvx 328): intramuscular powder for injection.

General adverse events

The most commonly reported side effects included erythema, injection site pain, fatigue, headache, myalgia, nausea, and swelling.^[Ref]

Dermatologic

• Very common (10% or more): Erythema (up to 13%)
• Common (1% to 10%): Severe erythema
• Postmarketing reports: Injection site erythema, rash, skin exfoliation^[Ref]

Erythema included any erythema 25 mm and greater.

Severe erythema included erythema over 100 mm.^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (up to 15%)
• Uncommon (0.1% to 1%): Severe nausea^[Ref]

Nausea included any nausea (i.e., mild [transient, no normal activity limitations], moderate [some daily activity limitations], and severe [unable to perform activities]).^[Ref]

Hematologic

• Uncommon (0.1% to 1%): Lymphadenopathy^[Ref]

Lymphadenopathy occurred within 1 to 30 days of vaccination.^[Ref]

Hepatic

• Postmarketing reports: Increased ALT^[Ref]

Hypersensitivity

• Uncommon (0.1% to 1%): Hypersensitivity or hypersensitivity reactions
• Postmarketing reports: Allergic reaction, anaphylactic reactions, anaphylaxis^[Ref]

Hypersensitivity developed within 9 to 27 days of vaccination.^[Ref]

Immunologic

• Postmarketing reports: Connective tissue disorder^[Ref]

Connective tissue disorder was reported in 1 patient who received 2 doses of this vaccine and a dose of a hepatitis A vaccine.^[Ref]

Local

• Very common (10% or more): Injection-side pain (up to 92%), injection-site swelling (up to 13%)
• Common (1% to 10%): Injection-site induration, severe injection-site pain, severe injection-site swelling
• Postmarketing reports: Blisters at or around injection site, extensive swelling of vaccinated limb, injection-site inflammation, injection-site nodule, injection site pruritus, injection-site reactions, vaccination site cellulitis^[Ref]

Pain included any pain (i.e., mild [transient, no normal activity limitations], moderate [some daily activity limitations], and severe [unable to perform activities]).

Swelling or induration included any swelling or induration of 25 mm or greater.

Severe swelling or induration included swelling/induration over 100 mm.

Injection-site nodules may persist for more than 1 month.^[Ref]

Musculoskeletal

• Very common (10% or more): Myalgia (up to 15%)
• Common (1% to 10%): Arthralgia, severe myalgia
• Uncommon (0.1% to 1%): Severe arthralgia
• Postmarketing reports: Bone pain^[Ref]

Myalgia and arthralgia included any myalgia or arthralgia (i.e., mild [transient, no normal activity limitations], moderate [some daily activity limitations], and severe [unable to perform activities]).^[Ref]

Nervous system

• Very common (10% or more): Headache (up to 42%)
• Common (1% to 10%): Severe headache
• Uncommon (0.1% to 1%): Dizziness, presyncope, syncope
• Postmarketing reports: Balance disorder, Bell's palsy, facial paresis, seizures, tonic convulsion, vasovagal responses to injection, vertigo, vestibular disorder^[Ref]

Dizziness, presyncope, and syncope occurred within 1 to 30 days after vaccination.

Headache included any headache (i.e., mild [transient, no normal activity limitations], moderate [some daily activity limitations], and severe [unable to perform activities]).

Seizures occurred in 1 patient 9 hours after administration of the first dose of this vaccine.^[Ref]

Ocular

• Postmarketing reports: Eyelid ptosis, eye swelling^[Ref]

Other

• Very common (10% or more): Fatigue (up to 51%)
• Common (1% to 10%): Fever or pyrexia, severe fatigue
• Uncommon (0.1% to 1%): Severe fever
• Postmarketing reports: Ear pain, fall, head injury, impaired hearing, increased body temperature, malaise^[Ref]

Fatigue included any fatigue (i.e., mild [transient, no normal activity limitations], moderate [some daily activity limitations], and severe [unable to perform activities]).

Fever included any fever 38C (100.4F) and greater.

Severe fever included fever of 40C (104F) and greater.^[Ref]

Respiratory

• Postmarketing reports: Oropharyngeal pain^[Ref]

Further information

Penmenvy side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer